DBV Technologies (DBVT) Cash from Investing Activities (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Cash from Investing Activities of -$600000.0 for Q2 2026, down 100.0% on a QoQ basis from -$300000.0 in Q1 2026.
DBV Technologies (DBVT) Cash from Investing Activities (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Cash from Investing Activities for 7 consecutive years, with -$600000.0 the latest figure, recorded in Q2 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$600000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.9 million (down 758.1% YoY) and the FY2025 annual result came in at -$1.4 million, down 80.85% from the prior year.
- Cash from Investing Activities eased to -$600000.0 in Q2 2026 per DBVT's latest filing, from -$300000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for DBVT reached as high as $793000.0 in Q4 2024 and fell as low as -$2.1 million in Q1 2024.
- A 5-year average of -$231411.8 and a median of -$229000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 524.06% in 2024 against a maximum downside of 5176.19% in 2024.
- Year by year, Cash from Investing Activities stood at -$34000.0 in 2022, then tumbled by 450.0% to -$187000.0 in 2023, then jumped by 524.06% to $793000.0 in 2024, then slumped by 190.16% to -$715000.0 in 2025, then advanced by 16.08% to -$600000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$600000.0, -$300000.0, and -$715000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -45.51 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 178,242.27 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 172.62 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -600,000.00 |
| Jun 30, 2026 | -600,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Mar 31, 2025 | -400,000.00 |
| Mar 31, 2025 | -400,000.00 |
| Dec 31, 2024 | 793,000.00 |
| Dec 31, 2024 | 793,000.00 |
| Sep 30, 2024 | -109,000.00 |
| Sep 30, 2024 | -109,000.00 |
| Jun 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 691,000.00 |
| Mar 31, 2024 | -2.13 Mn |
| Mar 31, 2024 | -2.13 Mn |
| Dec 31, 2023 | -187,000.00 |
| Dec 31, 2023 | -187,000.00 |